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Abstract
Many pharmaceuticals, either by accident or design, may exist in a total or partially amorphous state. Conse-
quently, it is essential to have an understanding of the physico-chemical principles underpinning the behaviour of such
systems. In this discussion, the nature of the glassy state will be described, with particular emphasis on the molecular
processes associated with glass transitional behaviour and the use of thermal methods for characterising the glass
transition temperature, Tg. The practicalities of such measurements, the significance of the accompanying relaxation
endotherm and plasticization effects are considered. The advantages and difficulties associated with the use of
amorphous drugs will be outlined, with discussion given regarding the problems associated with physical and chemical
stability. Finally, the principles of freeze drying will be described, including discussion of the relevance of glass
transitional behaviour to product stability. © 1999 Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The majority of solid drugs and dosage forms
are prepared in the crystalline state, characterised
by a regular ordered lattice structure. In practical
terms, the physical structures of these systems are
generally thermodynamically stable and are rela-
tively simple to study using techniques such as
differential scanning calorimetry and X-ray dif-
fraction. However, it has been recognized for a
considerable period of time that pharmaceutical
materials may also be prepared in an amorphous
form (Haleblian, 1975; Byrn, 1982), where there is
no long range order. The classic example of this
approach is that of novobiocin which was shown
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to exhibit favourable dissolution properties when
prepared in an amorphous as opposed to crys-
talline state (Mullins and Macek, 1960). Further-
more, processes such as freeze and spray drying
may lead to the generation of amorphous systems,
while grinding or conventional drying may result
in materials which are partially or wholly
disordered.
The amorphous state may arise as a result of
three sets of circumstances. Firstly, the drug, ex-
cipient or delivery system may be deliberately
produced in an amorphous form in order to en-
hance product performance characteristics. Exam-
ples of this strategy include the preparation of
glassy drugs for enhanced dissolution behaviour
or freeze drying, both of which will be discussed
in more detail in later sections. Secondly, the
material may be intrinsically at least partially
amorphous at room or body temperature, exam-
ples including D:L polylactic acid,
polyvinylpyrrolidone or polyethylene glycol. Con-
sequently, dosage forms prepared using these ma-
terials will inevitably be at least partially
amorphous. Thirdly, the amorphous state may be
generated accidentally, examples including
milling, drying and compression. In many ways
accidental production can prove to be the most
problematic, as the levels of disordered material
generated may be sufficiently large to cause
changes in product performance but also too
small to be easily detected.
While the preparation of amorphous systems
may be desirable, there are a number of
difficulties associated with their use. Amorphous
materials are thermodynamically unstable and
will tend to revert to the crystalline form on
storage (devitrification); such behaviour has been
well documented for a number of drugs (Fukuoka
et al., 1986; Yoshioka et al., 1994; Hancock et al.,
1995). It should be stressed at this point that the
onset of the devitrification process may be so slow
so as to be effectively irrelevant within the storage
time of a product, although an understanding of
the nature and characterisation of the glass transi-
tional behaviour is nevertheless essential in order
to enhance predictability of stability.
The mechanical properties and vapour sorption
profiles of amorphous systems may be markedly
different from the crystalline material (Hancock
and Zografi, 1997), while the chemical reactivity
of amorphous drugs may be greater (Pikal et al.,
1978). In addition, the behaviour of the system
below and above the glass transition temperature
(Tg, at which the material changes on cooling
from a liquid or rubbery state to a brittle state)
will differ; the rate of crystallisation is much
greater above Tg, while freeze dried products are
less likely to physically collapse if stored below
Tg. A further consideration which is particularly
pertinent to commercial uses of amorphous mate-
rials is the lack of a ‘comfort factor’ associated
with such systems. The physical structure of
glassy materials is more difficult to characterise
and quality control than is that of crystalline
systems. Similarly, the knowledge base concerning
the relationship between Tg and pharmaceutical
product performance is not fully developed. Fur-
thermore, considerable care must be taken with
regard to the use of conventional accelerated sta-
bility studies in order to predict chemical or phys-
ical stability, as the behaviour above and below
Tg is not directly comparable (Duddu and Dal
Monte, 1997). In common with phenomena such
as polymorphism, the characteristics of amor-
phous drugs must also be considered in the light
of regulatory requirements (Byrn et al., 1995).
These difficulties have led to a number of in-
stances whereby the use of amorphous drug forms
has been rejected as a formulation strategy by
pharmaceutical companies, despite the fact that
this route offers a potential means of considerably
enhancing product performance.
The subject of glassy systems has received con-
siderable attention in other fields such as the
polymer and food sciences (Wunderlich, 1990;
Slade and Levine, 1991, 1995) and the interested
reader is referred to these and related texts for
more detailed information. Similarly, the reviews
by Hancock and Zografi (1997) and Kerc’ and
Src’ ic’ (1995) are also recommended, the former
containing a detailed discussion of the nature of
the glassy state of pharmaceuticals and the latter
placing emphasis on published examples of amor-
phous drug systems, with particular consideration
of thermal analysis. Given the breadth that the
topic of amorphous pharmaceutical systems has
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now assumed, it is not possible to cover all as-
pects of the subject in a single review. In this
discussion, therefore, the basic principles under-
lining the behaviour of amorphous materials will
be described, with particular emphasis on charac-
terisation of these systems using thermal analysis.
In terms of applications, the discussion will be
confined to glassy drugs and freeze dried materi-
als, as these are two of the most important sys-
tems in which the amorphous state may be
encountered.
2. The amorphous state and glass transitions
2.1. The generation of amorphous materials by
cooling from the melt
While partially or wholly amorphous solids
may be generated via a number of routes, most
texts describing glassy systems work on the basis
that the material has been formed by rapid cool-
ing from the melt. For simplicity, this will also be
assumed in the forthcoming description of the
theoretical basis of glass formation, although in
practice processes such as solvent precipitation or
milling may also lead to the generation of amor-
phous systems. A number of texts are available
for more information on the nature of the glass
transition (Elliott, 1983; Wunderlich, 1990; An-
gell, 1995a; Hancock and Zografi, 1997).
The essential differences between the formation
of amorphous and crystalline systems may be
illustrated with respect to Fig. 1. For crystalline
systems, decreasing the temperature from the liq-
uid state to the melting point (Tm) results in a
transition to the crystalline form (assuming no
supercooling), which below Tm is the thermody-
namically stable state with respect to non-crys-
talline forms. The exothermic crystallisation
process leads to a sudden contraction of the sys-
tem due to a decrease in free volume (defined as
the difference between the total volume and the
actual volume displaced by the constituent
molecules). Consequently, both the enthalpy (H)
and specific volume (V) decrease at Tm. Further
less marked decreases in the above may be seen as
the temperature is lowered as a result of heat
capacity and thermal contraction effects. It should
be noted, however, that in the case of water,
crystallisation leads to expansion rather than
contraction.
In the case of a glass-forming material, the
cooling process is too fast for the crystallisation
process to take place, either due to the use of a
rapid rate of cooling or the crystallisation process
being unfavoured because of molecular size and
shape (as is the case with the majority of
proteins). No discontinuity in enthalpy or volume
is seen on cooling the material below Tm and the
system forms a supercooled liquid. As the mate-
rial is cooled further, a point is reached at which
the material becomes ‘frozen’ into the glassy state.
At this temperature, the bonding between
molecules remains essentially the same as that of
the liquid but the translational and rotational
motions of those molecules are dramatically re-
duced, with principally vibrational motions taking
place below Tg. The glass transition will thus be
characterised by a step change in heat capacity Cp
which is the derivative of enthalpy with respect to
temperature (((H:(T)p), hence the transition is
dependent on molecular mobility with no associ-
ated heat transfer for the process. The transition
Fig. 1. Schematic illustration of the change in volume or
enthalpy with temperature for a material undergoing crystalli-
sation or a glass transition. The first-order crystallisation at
Tm is shown in conjunction with the discontinuity in volume:
enthalpy at Tg. The short-dashed line indicates the behaviour
of a system cooled at a slower rate than that corresponding to
the solid line. The long-dashed line shows the Tg values for the
fast cooled (Tg1) and slow cooled (Tg2) systems [adapted from
Elliott (1983)]
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is rate dependent, with slower cooling rates result-
ing in lower values for Tg, as indicated in Fig. 1.
In practical terms, the material is considered to be
in the liquid (or ‘rubbery’ in the case of some
polymers) and glassy states above and below Tg,
respectively. In the case of many polymers the
mechanical properties of the system change from
those of a pliable to a brittle material as the
system is cooled through the glass transition,
these changes arising as a result of the decrease in
molecular motions.
There are a number of theories associated with
the nature of the glass transition but, as yet, there
is no universally accepted single explanation for
the phenomenon. The observation that Tg is rep-
resented by a change in the derivative of extensive
thermodynamic parameters such as volume, en-
thalpy and entropy suggests that the glass transi-
tion is a second order thermodynamic phase
transition, where the term second order refers to
the order of the lowest derivative of the Gibbs
free energy which shows a discontinuity at the
transition point (processes such as crystallisation
being first order). However, there are a number of
difficulties associated with this explanation, not
least of which is the common observation that the
value of Tg is dependent on cooling rate. As a
second order thermodynamic transition is by defi-
nition rate independent, the glass transition is not
ideally second order.
It is also helpful to consider the entropy of the
system, which at equilibrium is related to the heat
capacity via CpT ((S:(T)p The heat capacities
of the glassy (BTg) and crystalline states for a
given material are essentially the same and arise
principally from vibrational contributions, while
the higher values of Cp observed at temperatures
\Tg are caused by the material possessing addi-
tional configurational degrees of freedom when in
the rubbery state. Consequently, the Tg may be
considered to occur at a given value of excess
entropy (Elliott, 1983). Kauzmann (1948) ad-
dressed the question of the temperature depen-
dence of Tg, in particular whether there is a lower
limit to the value of the glass transition at infi-
nitely long cooling times. It was suggested that
such a lower limit does indeed exist and is gov-
erned by the fact that if the Tg represents a loss of
excess entropy, that value may not exceed the
entropy associated with the change from the liq-
uid to the crystalline form (i.e. the entropy of
fusion). Otherwise, the entropy of the glass would
be lower than that of the crystal which would
violate the third law of thermodynamics. This
situation is known as the Kauzmann paradox and
is resolved by there being a lower limit to Tg for
any system (termed either the calorimetric ideal
glass transition temperature Toc or the Kauzmann
temperature Tk). In practice, the experimental Tg
may occur 20 K or more above Tk. It may
therefore be postulated that, over and above the
possibility of a second order phase transition tak-
ing place, the heat capacity will decrease with
temperature in any case as a result of equilibrium
thermodynamics. On this basis, the glassy be-
haviour of materials may be considered to be a
function of their configurational entropy, hence it
should theoretically be possible to relate the Tg
value to the ‘stiffness’ of the molecule in question.
This has been discussed in detail for linear poly-
mers (Gibbs and Di Marzio, 1958; Gibbs, 1960;
Gee, 1970).
The glass transition may also be considered in
terms of the relaxation processes that occur as the
liquid is cooled. These relaxation times will be
temperature dependent, with longer times being
observed as the liquid is cooled; for hydrogen-
bonded fluids, these relaxation processes will be
governed largely by reorganisation of those hy-
drogen bonds. If the ‘structural’ relaxation time of
the material (tr) is short with respect to the time
of observation t0 (which will be the case at tem-
peratures above Tg) then the material will appear
‘liquid-like’ as the sample will be able to respond
to changes in temperature within the timescale of
the cooling process. Consequently, above Tg the
sample is in equilibrium with the cooling pro-
gramme. Below Tg, however, t0 will be Btr, hence
the material will assume solid-like characteristics
due to the relaxation process being slow with
respect to the timescale of the cooling pro-
gramme, leading to reduced molecular mobility.
Tg may therefore be considered to occur when
tr: t0. A related approach to interpreting the
glass transition is to consider the free volume of
the system. This model was developed for fluids
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(Cohen and Turnbull, 1959; Turnbull and Cohen,
1961, 1970) and considers the liquid to be com-
posed of a volume occupied by the constituent
molecules (Vocc) and a volume in which the
molecules are free to move (the free volume Vf).
The free volume is composed of voids of varying
sizes which are continuously redistributed through
the system via random movements of the con-
stituent molecules. It is further assumed that the
molecules may diffuse through the system only
when the free volume is above a critical value. As
the temperature is lowered, both volumes con-
tract. For a glassy system, the free volume reaches
a lower limit at Tg and is thereafter temperature
independent, hence in essence the glass transition
occurs when Vf falls below a critical value (Fox
and Flory, 1950, 1951, 1954).
The relaxation behaviour of glassy systems may
be associated with molecular mobility and macro-
scopic fluidity, which in turn determine many of
the important properties of the amorphous mate-
rials. These properties will therefore be outlined
separately in a subsequent section. However, the
above discussion illustrates the difficulty in estab-
lishing an exact definition of the glass transition.
The process has been described as a second order
thermodynamic phase change (although, as previ-
ously stated, the rate dependence of the process
weakens this interpretation considerably), as an
equilibrium process involving excess entropy or as
a kinetic relaxation process. In practice, it is usual
to work on the basis of the process being essen-
tially kinetic, hence the Tg is considered to be a
function of the relaxation behaviour of the mate-
rial. It is important to stress, however, that this is
not the only interpretation of this event.
2.2. The 6iscosity of glasses
At the Tg, the viscosity of the liquid attains a
value in the region of 1012–1014 Pa.s, while above
the glass transition the material may show consid-
erable temperature dependence in the viscosity
value, as shown in Fig. 2. The extent and nature
of this temperature dependence itself varies be-
tween materials. ‘Strong’ glass formers such as
SiO2 which form networks in the liquid state obey
the Arrhenius relationship over a wide tempera-
Fig. 2. Viscosities of a variety of glass-forming systems as a
function of reduced reciprocal temperature. The curves have
been normalised such that the glass-transition temperature is
defined to be when h1013 Poise (Reprinted from Glass:
structure by spectroscopy, J. Wong and C.A. Angell, Marcel
Dekker, New York, Copyright (1976), with permission from
Elsevier Science).
ture range, while ‘fragile’ glass formers such as
organic glasses (e.g. O-terphenyl and i-butyl bro-
mide) show strong deviation from such behaviour
(Wong and Angell, 1976). In the region immedi-
ately above Tg, such materials may follow the
Vogel–Tammann–Fulcher (VTF) relationship
which may be expressed in terms of the relaxation
time t via:
tt0 exp (DT0:TT0) (1)
where T is the temperature and t0, D and T0 are
constants. As can be seen from Fig. 2, systems
obeying this relationship show a temperature-de-
pendent activation energy as opposed to the con-
stant value predicted by the Arrhenius
relationship. A related empirical expression is the
Doolittle equation (Doolittle, 1951) which relates
the viscosity to the free volume of the sample via:
hA exp (BVocc:Vf) (2)
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where A and B are constants, if the thermal
expansion of the system is linear with temperature
then Eq. (1) may be obtained from the Doolittle
equation. Alternatively, the Williams–Landel–
Ferry (WLF) equation (Williams et al., 1955), a
special case of the VTF equation, has been shown
to be applicable to a wide range of glass forming
systems whereby:
hhg exp [C1(TTg):(C2 (TTg))] (3)
where hg is the mean viscosity at Tg and C1 and C2
are constants. This equation allows calculation of
the relaxation times of the system over a range of
temperatures and therefore allows prediction to be
made with regard to temperature-dependent be-
haviour. As will be demonstrated later, these rela-
tionships may be highly important in
understanding the behaviour of pharmaceutical
products.
Strong glass-formers exhibit minimal molecular
mobility changes at Tg, hence the shift in heat
capacity tends to be small. Conversely, fragile
glass-forming systems exhibit marked changes in
mobility through the Tg due to their non-direc-
tional, non-covalent interactions, hence the heat
capacity alterations at Tg are larger (Angell, 1995a)
and easier to detect. A ‘rule-of-thumb’ with regard
to predicting the fragility has been proposed (Slade
and Levine, 1995; Angell, 1995a,b) whereby if
Tm:Tg is less or greater than 1.5 the glass can be
considered fragile or strong, respectively. Unfortu-
nately, native globular proteins are generally
strong glass forming systems, hence the heat capac-
ity changes associated with Tg tend to be small
which renders their measurement using thermal
methods more difficult. The glassy behaviour of
proteins has been the subject of considerable dis-
cussion (Doster et al., 1989; Frauenfelder et al.,
1991; Green et al., 1994) and, given the preponder-
ance of proteinaceous drug molecules under devel-
opment, this area may represent a subject of
considerable future interest within the pharmaceu-
tical sciences.
2.3. A6ailable methods for the measurement of Tg
As Tg is associated with a change in molecular
mobility, the transition will consequently affect
many of the material’s physical characteristics. It
is therefore possible to detect glass transitional
behaviour by changes in volume:density, heat ca-
pacity, viscoelastic moduli, electrical permittivity
and refractive index. There are a number of avail-
able methods by which the glass transition may be
studied and the interested reader is referred to the
text by Hancock and Zografi (1997) for a more
detailed discussion of these approaches along with
other methods such as NMR. In the present text
the use of thermal methods will be outlined. The
simplest method with which to measure the change
in heat capacity associated with the glass transition
is differential scanning calorimetry (DSC). This
technique lends itself to the measurement of Tg
values for small quantities of powdered material,
which is the most likely state in which an amor-
phous pharmaceutical system will be presented to
the analyst. Other thermal approaches include
thermomechanical analysis (TMA), whereby the
dimensional changes of a sample are measured as
a function of temperature. This method is usually
employed for the measurement of polymeric films,
although in practice cast films of a range of
amorphous materials may be analysed (Hancock et
al., 1995).
The change in the viscoelastic properties of an
amorphous material with temperature can be mea-
sured by dynamic mechanical analysis (DMA,
Craig and Johnson, 1995; Haines, 1995). An oscil-
latory stress is applied to the sample and both the
magnitude and phase relationship of the stress and
strain values are measured as a function of either
frequency or temperature. When the sample is
heated through the glass transition the shear mod-
ulus decreases, often by several orders of magni-
tude. The ratio of the loss and storage modulus is
equal to tan d, and the glass transition is seen as
a peak in tan d when plotted against temperature.
Andronis and Zografi (1997) have described the use
of DMA for the determination of the glass transi-
tional behaviour for amorphous indomethacin.
Dielectric analysis (DEA) is another oscillatory
technique, but in this case a sinusoidal oscillatory
electric field is applied to the sample. The complex
dielectric permittivity is measured as a function of
temperature and may change abruptly through the
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glass transition, thereby allowing identification of
the Tg (McCrum et al., 1967).
2.3.1. The measurement of Tg by differential
scanning calorimetry
DSC is the most frequently used technique for
the measurement of glass transitional behaviour.
The method involves the heating or cooling of a
sample and reference and the measurement of the
differential heat flow (power) between them with
respect to temperature (or, less usually, time).
There are two principal approaches to such mea-
surements. Heat flux DSC involves the measure-
ment of the temperature differential between the
sample and reference and the subsequent calcula-
tion of the equivalent heat flow, as given by:
DQ (TsTr):RT (4)
where Q is heat, RT is the thermal resistance of
the cell and Ts and Tr are the sample and refer-
ence temperatures, hence at a given scanning rate
the heat flow (power, P) is obtained and displayed
against temperature.
Power compensation DSC involves the applica-
tion and measurement of a compensatory power
input (P) to one or other pan in order to maintain
both at the same programme temperature, hence:
PI2R (5)
where I is the current supplied to the heater of
resistance R in order to maintain equality of
temperature.
As power is energy per unit time and the sam-
ple is being heated or cooled at a predetermined
rate, in effect the instrument is measuring the
difference in energy required to raise the tempera-
ture of either sample or reference by a unit
amount, i.e.
PdQ:dtCp·dT:dt f(t, T) (6)
where f(t, T) is a function of temperature and
time and reflects kinetically controlled events such
as melting and crystallisation. In essence, there-
fore, DSC is measuring the difference in apparent
heat capacity between the two pans. Conse-
quently, the glass transition is seen as a step in the
baseline which allows identification of both the
temperature and, with suitable calibration, quan-
tification of the DCp value, although the latter has
not been extensively employed in the study of
pharmaceutical systems. It should also be pointed
out that, due to the scaling direction on the
ordinate, power compensation DSC shows en-
dotherms and exotherms pointing upwards and
downwards respectively, while heat flux instru-
ments show the opposite.
Fig. 3 shows an idealised sketch of a typical
glass transitional response measured using DSC,
the response being expressed in terms of the
change in heat capacity. Tg is preferably specified
as the temperature of half vitrification on cooling,
i.e. the temperature at which the heat capacity is
midway between the liquid and glassy state (Wun-
derlich, 1990). It is determined by the extrapola-
tion of the Cp (or power) plots for the glass and
the liquid:rubber state, with Tg given as the mid-
point between the two lines. In addition the glass
transition range and onset can be used to charac-
terise this region. The beginning of the transition
is given by Tb, whereas the extrapolated onset
temperature is T1. Similarly, the extrapolated end-
point is T2 and the transition end is given by Te.
However, in practice the use of parameters such
as Tb and Te may be limited by the difficulties
Fig. 3. Schematic representation of the change in heat capacity
through the glass transition, indicating the various parameters
that may be used to express the glass transitional behaviour
(Reprinted from Thermal Analysis, B. Wunderlich, Academic
Press, London, Copyright (1990), with permission from El-
sevier Science).
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associated with distinguishing the beginning and
end of the transition from the baseline.
It is important to note that the value of the
glass transition depends on the heating and cool-
ing rate. As illustrated in Fig. 1, a fast cooling
rate produces a higher value for Tg than does the
use of slower rates (Richardson and Savill, 1975).
This relationship may be described in terms of the
relaxation behaviour of the system. The time scale
for the relaxation processes is higher at lower
temperatures, i.e. the relaxation will be slower
(Moynihan et al., 1974). Consequently, at slower
rates the temperature at which the relaxation pro-
cess becomes comparable with the time scale of
the experiment will be lower, hence the measured
Tg will be lower. This issue is a source of consider-
able confusion when constructing quality control
tests, as unlike melting which is independent of
heating rate, the glass transition is a response to a
heating or cooling signal and hence will vary
depending on the method of measurement.
The difficulty of scanning rate dependence may
be overcome by use of the fictive temperature Tf,
which represents the temperature at which the
extrapolated enthalpies above and below to the
glass transition are equal. As described above, the
glass transition is a kinetic event and therefore
highly dependent on the heating or cooling rate of
the temperature programme. However, the true
value for the glass transition temperature is only
dependent on the conditions of formation, e.g. on
the cooling rate of the sample in the case of
quenching. The heating rate dependence is seen
because DSC is a dynamic technique, leading to
possible differences in the experimental and
molecular time scales. Consequently, analysis of
the transition on heating will not give the ‘true’ Tg
value, but a dynamic glass transition temperature
dependent on the underlying heating rate. To
remove this problem, Richardson and Savill
(1975) have suggested measurement of the fictive
temperature which is independent of heating rate.
This method involves raising the temperature
from a steady value below the glass transition
region, T1, to a steady value above Tg, T2, and,
using suitable calibration, recording the specific
heat as a function of temperature, i.e.
Fig. 4. Schematic representation of the fictive temperature,
showing the extrapolation of the enthalpy curves below and
above Tg for a quenched (Tgq) and annealed (Tga) glass. The
solid lines depict typical experimental paths, while the dashed
line shows how the fictive Tg is defined [adapted from Richard-
son and Savill (1975)].
Cpgabt, CplABT (7)
where Cpg and Cpl are the specific heat capacities
of the glassy and liquid states and a, b, A and B
are constants determined by linear regression. In-
tegration of these equations gives:
Hg(T)aT1:2 bT2P,
Hl(T)AT1:2 BT2Q (8)
where P and Q are constants. The fictive tempera-
ture is defined as the intersection of the extrapo-
lated enthalpy curves and is obtained by solving
for the quadratic for T when Hg(T)Hl(T). is
shown schematically in Fig. 4. The value may also
be determined via calculation of the areas under
the experimental heat capacity curves; interested
readers are referred to the work by Moynihan et
al. (1976) and Moynihan (1994) for more details.
Use of the fictive temperature could have several
advantages as far as pharmaceutical systems are
concerned, particularly in terms of establishing
reliable quality control protocols.
A further, often considerable problem associ-
ated with the measurement of Tg using DSC is the
presence of a relaxation endotherm; this feature is
seen on heating as an endothermic response su-
perimposed on the baseline shift which may ren-
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der identification and quantification of the Tg
extremely difficult (an example of an amorphous
drug showing this behaviour is given in Fig. 5).
Indeed, for complex or multicomponent samples
such as freeze dried formulations it may be ex-
tremely difficult to differentiate between a glass
transition and a melting response, although differ-
ences in rate dependence of the relaxation and
melting endotherms may allow distinction be-
tween the two. The relaxation endotherm may
arise as a result of one of two processes. Firstly, it
may reflect a mismatch in the rate of cooling and
subsequent heating of the sample. This may be
explained with reference to Fig. 6. When cooling
is slow the glass that forms has long relaxation
times ‘frozen in’. Subsequently, when this material
is heated quickly, with a faster rate through the
glass transition than was the case on cooling, the
relaxation times are slow with reference to the
heating rate, thereby producing an overshoot in
the enthalpy curve. In other words, the molecules
within the glass cannot achieve the motion re-
quired for the glass transition within the time
scale of the heating rate and the glass briefly
superheats (Wunderlich, 1990). Once the relax-
ation times lower to the order of the heating rate
the superheated glass reverts quickly towards the
liquid line in the enthalpy curve. This overshoot
and subsequent recovery in the enthalpy curve
produces the characteristic endothermic peak in
the DCp (or power) curve. The second reason for
the appearance of the endothermic relaxation is
that because glasses are not in an equilibrium
state, they can relax over time, thereby decreasing
the enthalpy and volume of the material and
increasing the structural relaxation time. Conse-
quently, such annealing also produces a relaxation
endotherm at the glass transition for the same
reasons as above, the magnitude of which may be
used to calculate relaxation times for the sample
(Montserrat, 1989; Hancock et al., 1995), this is
described in more detail in Section 3.2.
There are a number of difficulties associated
with the presence of relaxation endotherms. Over
and above problems in identifying glass transi-
tions, the quantification of both the Tg value and
the relaxation endotherm may be difficult, as illus-
trated in Fig. 5. It is not clear, for example,
exactly where under the peak the Tg lies (although
the fictive temperature may be of use in this
Fig. 5. Glass transition of saquinavir, showing the relaxation endotherm associated with Tg (Reprinted from Pharm. Res., 15, P.G.
Royall, D.Q.M. Craig and C. Doherty, Characterisation of the glass transition of an amorphous drug using modulated DSC, pp.
1117–1121, Copyright (1988), with permission from Elsevier Science).
D.Q.M. Craig et al. : International Journal of Pharmaceutics 179 (1999) 179–207188
Fig. 6. Schematic representation of the origin of the relaxation
endotherm caused by a mismatch in cooling and heating rates.
The figure shows the enthalpy and corresponding heat capac-
ity changes through the Tg region on slow cooling and fast
heating.
true glass transition will be reproducible and
should be seen on both heating and cooling (given
the provisos listed above). Furthermore, it is es-
sential that adequate baseline calibration is per-
formed to ensure as flat a baseline as possible; if
extensive bowing is present then quantitative iden-
tification of the Tg will be extremely difficult.
Baseline calibration is achieved by subtraction of
the response from two empty DSC pans in the
reference and sample positions. It is also possible
to use higher scanning rates to aid visualisation of
the Tg. Inspection of Eq. (6), for example, indi-
cates that at higher values of dT:dt, the heat flow
will be greater, hence the sensitivity of the mea-
surement may be improved (although there will
inevitably be a concomitant loss of resolution);
the influence of the heating rate on the glass
transition value should, however, be noted. Great
care is required if the DCp value at Tg is to be
measured quantitatively, as it is essential to per-
form adequate reference calibration using a stan-
dard such as sapphire in order to obtain
meaningful data.
Sample preparation conditions must be care-
fully controlled (and stated), particularly in terms
of the choice of pans and level of residual mois-
ture or other solvents, as otherwise changes to the
sample either during or prior to analysis may have
a profound influence on the measured Tg. A re-
cent investigation (Hill et al., 1998) indicated that
the measured Tg of spray dried lactose may vary
by :35°C depending on pan type. This is due to
the retention of water in hermetically sealed pans
which acts as a plasticizer (discussed below),
thereby reducing Tg compared to non-hermeti-
cally sealed or open pans from which water is lost
during the heating run.
Tg measurements are, ideally, performed in
cooling rather than heating cycles, as in the for-
mer the sample starts from the equilibrium liquid
state before entering the nonequilibrium glass,
which is a reproducible route compared to start-
ing from the glass in a heating cycle (Wunderlich,
1990). However, as mentioned above, many phar-
maceutical systems such as drugs and freeze dried
systems are heat sensitive and may not withstand
cycling. Similarly, other systems are multicompo-
nent, hence heating through the Tg of one compo-
respect), hence it is also difficult to calculate the
value of the relaxation enthalpy. This may be
overcome by controlling the thermal history of
the sample, particularly by heat:cooling which
should remove annealing effects. However, this
may not be appropriate for pharmaceutical sam-
ples which are often multicomponent and hence
may not be reversibly temperature cycled. An
alternative approach involves the use of modu-
lated temperature DSC, which allows separation
of the relaxation endotherm from the glass transi-
tion, although Royall et al. (1988) have identified
certain provisos associated with such measure-
ments. This technique is discussed in more detail
below.
In addition to the above, there are also a num-
ber of practical considerations associated with the
measurement of glass transitions using DSC. The
baseline shifts may be small, particularly for
strong glasses, rendering differentiation from
baseline noise a non-trivial problem. However, a
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nent may result in irreversible changes in the
structure of the system as a whole. Consequently,
most pharmaceutical studies have involved mea-
suring Tg upon heating.
The development of MTDSC has removed or
lessened some of the difficulties associated with
characterising glass transitions. This technique
represents a change in the software of the conven-
tional DSC and, in the model marketed by TA
Instruments (modulated DSC, MDSC) involves
the application of a sinusoidal heating signal su-
perimposed on the linear programme, hence infor-
mation may be derived from both the sine wave
response and the Fourier transformed total heat
flow output (equivalent to conventional DSC).
The advantage of the technique is that changes in
heat capacity (i.e. glass transitions) may be seen in
isolation from other events, particularly relax-
ation endotherms, with a considerably enhanced
signal-to-noise ratio. An example of this is shown
in Fig. 7 for the amorphous drug saquinavir.
More details of this technique are available else-
where (Royall et al., 1988; Reading et al., 1993;
Coleman et al., 1996; Hill et al., 1998) and the
method is expected to make a major contribution
to the assessment of glassy pharmaceuticals.
2.4. Plasticization of amorphous materials
A highly important consideration with regard
to the glass transition of amorphous materials is
the effect of the presence of additional materials,
particularly water, on the value of Tg. The study
of mixed systems has been of particular impor-
tance in the polymer science field, whereby mate-
rials may be multicomponent, with the degree of
mixing being estimated by observing the glass
transitions of the product in relation to those of
the individual components. Mixing of amorphous
pharmaceuticals is an approach that may be used
to raise the glass transition of a product in order
to improve stability (Fukuoka et al., 1989).
The work on which amorphous mixing theory
is based is that of Gordon and Taylor (1952),
which was originally used to describe the be-
haviour of polymer blends. The Gordon Taylor
equation is based on free volume theory and gives
the glass transition, Tgmix, of a binary mixture,
Fig. 7. Separation of the DSC response of amorphous saquinavir into the reversing and non-reversing signals, in which the glass
transition and relaxation endotherm may be seen in isolation (Reprinted from Pharm. Res., 15, P.G. Royall, D.Q.M. Craig and C.
Doherty, Characterisation of the glass transition of an amorphous drug using modulated DSC, pp. 1117–1121, Copyright (1988),
with permission from Elsevier Science).
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assuming no specific interaction between the two
components, via:
Tgmix81Tg182Tg2 (9)
where 8 is the volume fraction and the subscripts
represent the two components. The volume frac-
tion can be described in terms of the weight
fraction of the components w, as 8 (wDa):r,
where Da is the change in thermal expansivity at
Tg and r is the density of the material. Redefining










which can be simplified by application of the
Simha–Boyer rule to:
Kr1Tg1:r2Tg2 (12)
K can be considered the ratio of the free volumes
of the two components. The goodness of fit of
experimental data to the Gordon–Taylor equa-
tion gives an idea of the ideality of mixing of two
components, as well as providing a predictive tool
for assessing the effects of different levels of a
second material on Tg. In terms of pharmaceutical
systems, the area in which this approach has
proved to be particularly important is in the study
of the effects of water on the glass transition. It is
well recognised that residual water levels may be
an important factor in determining chemical sta-
bility and mechanical properties. However, water
will also have a profound effect on the glass
transition of amorphous pharmaceuticals, acting
as a plasticizer by increasing the free volume of
the material, hence leading to a decrease in Tg.
Exactly the same principle applies to the inclusion
of plasticizers in polymeric film coats, although in
the light of the systems discussed in the next
section the question of water sorption will be
emphasised here.
In the amorphous state considerably more wa-
ter may be taken up relative to the crystalline
form (Hancock and Zografi, 1997), effectively due
to absorption of water into the solid, hence in
Fig. 8. Variation in the glass transition of freeze dried lactose
with water content. Solid line is the predicted behaviour from
Eq. (8)(Reprinted from Pharm. Res., 11, B.C. Hancock and G.
Zagrafi, The relationship between the glass transition tempera-
ture and the water content of amorphous pharmaceutical
solids, pp. 1166–1173, Copyright (1994), with permission from
Elsevier Science).
contrast to crystalline systems the uptake process
tends to be dependent on sample mass rather than
surface area. A typical profile of Tg against water
uptake is shown in Fig. 8 (Hancock and Zografi,
1994). As the concentration of water in the solid
increases, the Tg is seen to decrease according to
the Gordon–Taylor equation (or an approxima-
tion of this relationship if the system is non-ideal).
At any particular temperature, therefore, the sys-
tem may change from the glassy to the rubbery
state if water uptake takes place, with concomi-
tant implications for chemical degradation or de-
vitrification (discussed below). Ahlneck and
Zografi (1990) have emphasised that at higher
storage temperatures, a lower amount of water is
required to lower the Tg to that particular temper-
ature (Fig. 9). As a general principal, this has
profound implications for accelerated stability
testing of amorphous pharmaceuticals. Hancock
and Zografi (1994) have reported that water is a
potent plasticizer for a wide range of pharmaceu-
tical materials including PVP, lactose, starch, su-
crose and others.
3. Relevance of the glassy state to amorphous
drugs
There are numerous ways in which the amor-
phous state is of relevance pharmaceutically and a
full discussion of all such considerations would be
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prohibitively lengthy. Instead, this and the follow-
ing section will focus on two of the most impor-
tant aspects of glassy pharmaceuticals, namely
amorphous drugs and freeze dried systems.
3.1. Amorphous drugs and dissolution beha6iour
It is well recognised that, for many drugs, disso-
lution within the gastrointestinal tract may be the
rate limiting step to absorption, hence improve-
ment in the dissolution rate may enhance the
bioavailability of that drug. One approach to such
improvement is to prepare the drug in an amor-
phous form, the higher molecular mobility of this
form compared to the equivalent crystalline mate-
rial may lead to enhanced dissolution rate and
bioavailability, although there are important dis-
advantages to the approach which will be dis-
cussed below.
From the discussion given above, it is clear that
the basic physico-chemical parameter that may be
used to characterise amorphous drugs is the glass
transition temperature. Kerc’ and Src’ ic’ (1995)
have prepared a highly useful compilation of Tg
and melting point (Tm) data for a number of
drugs which is reproduced in Table 1. It should be
born in mind that the conditions under which the
various samples were prepared and measured are
highly unlikely to be uniform, hence absolute
comparisons between data points may not be
applicable. Furthermore, it is extremely difficult in
practice to remove all of the water associated with
such samples, hence plasticization may have taken
place in some cases. Nevertheless, a number of
useful trends may be extracted from the data. In
particular, the authors have discussed the signifi-
cance of the ratio between the glass transitional
and melting parameters, as Tg:Tm tends to be
:0.5 for symmetrical polymers and 0.7 for asym-
metrical (Gujrati and Goldstein, 1980), this refers
back to the concept of fragile and strong glasses
outlined in Section 2.2, although here the ratio is
inverted. Kerc’ and Src’ ic’ (1995) report values be-
tween :0.6 and 0.8 for low molecular weight
pharmaceuticals, which are slightly higher than
those found for polymeric systems. According to
the ‘rule of thumb’ of Tm:Tg ratios outlined ear-
lier, this indicates that low molecular weight phar-
maceutical systems are more fragile glass-forming
systems than polymers. The knowledge of this
ratio is of use as it does allow the formulator to
make a rough estimate of where a glass transition
is likely to be found for a drug with a known
melting point.
A number of examples of enhanced dissolution
for amorphous drugs are available in the litera-
ture. For example, 9,3%%-diacetylmidecamycin
(MOM), a 16-membered macrolide antibiotic, was
prepared in the crystalline and amorphous forms
and the dissolution behaviour of both at a range
of temperatures compared (Sato et al., 1981).
Figs. 10 and 11 show the corresponding dissolu-
tion profiles for the two forms; the amorphous
form clearly shows higher dissolution rates, al-
though at longer dissolution times the concentra-
tion in water decreases due to the formation of
crystalline MOM from the supersaturated solu-
tion. Similarly, the dissolution rate of amorphous
indomethacin has been reported to be greater
than for the crystalline material (Fukuoka et al.,
1986) as shown in Fig. 12 for water–ethanol and
water systems. Interestingly, these authors also
studied the relaxation behaviour of the glassy
system on storage below Tg, showing that while
quench cooled indomethacin was stable over a 2
year period at room temperature, pulverised
Fig. 9. Effect of relative humidity in the glass transition
temperature of PVP K30. The box illustrates conditions typi-
cally used in accelerated storage testing (Reprinted from Int J.
Pharm., 62, C. Ahlneck and G. Zografi, The molecular basis
of moisture effects on the physical and chemical stability of
drugs in the solid state, pp. 87–95, Copyright (1990), with
permission from Elsevier Science, data compiled from Ok-
sanen (1992)).
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Table 1
Glass transition (Tg) and melting point (Tm) data for a range
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334 483Chlormadinone acetate 0.69
336b-Estradiol-3-benzoate 472 0.71
337Amlodipine besylate 467 0.72






Nicardipin hydrochloride 358 0.81440
Griseofulvin I 362 0.86422
0.81Brucine 365 451
370 0.74497Griseofulvin II
371Chenodeoxycholic acid 436 0.85
0.84447Deoxycholic acid 377
0.79477Ursodeoxycholic acid 378
Cholic acid 393 0.83473
amorphous drug crystallised over a period of
months.
Amorphous drugs may be prepared in a num-
ber of ways such as rapidly cooling from the melt
or precipitation from suitable solvent systems.
Drying or grinding may deliberately or acciden-
tally induce amorphous characteristics. A ground
mixture of griseofulvin and microcrystalline cellu-
lose significantly improved both the dissolution
rate and bioavailability of the drug compared to a
micronised griseofulvin powder preparation (Ya-
mamoto et al., 1974). This was ascribed to an
increase in amorphous content of the drug as a
result of the grinding process. Grinding of pheny-
toin with microcrystalline cellulose was also found
to enhance drug dissolution rate, this again being
attributed to the formation of an amorphous
form of the drug (Yamamoto et al., 1976).
Spray drying may also be used to prepare
amorphous systems. A review of the physical
structure of spray dried products, with special
reference to thermal analysis, has been given by
Corrigan (1995). The formation of amorphous
pharmaceuticals via this process has been demon-
strated for a number of drugs such as digitoxin
(Nurnburg, 1976) and a range of thiazide diuretics
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Fig. 10. Concentration-time curves for crystalline MOM in
distilled water at various temperatures [reproduced from Sato
et al. (1981)].
(MAT) were spray dried using a range of inlet
temperatures (Yamaguchi et al., 1992). The au-
thors performed storage studies on the samples at
temperatures BTg, finding that materials prepared
using inlet temperature between Tg and Tm were
more stable than those prepared at lower or higher
temperatures, even though the storage conditions
were identical for the various samples.
These studies touch on one of the questions
which, to date, does not appear to have been fully
answered, namely to what extent can the amor-
phous ‘form’ of a drug vary depending on manu-
facturing or processing conditions? It is predictable
from basic theory that changing the preparation
conditions such as cooling rate from the melt or the
presence of trace plasticisers (particularly water)
may alter the Tg (and hence ‘structure’) of the
material. For example, Kerc’ et al. (1991) have
reported (comparatively small) changes in the Tg
value of felodipine on altering the cooling rate from
the melt. However, marked changes in the dissolu-
tion rate were observed depending on cooling
conditions (Fig. 13), even though the glass transi-
tion values for systems cooled at 1°C:min and those
cooled at the maximum set rate of the instrument
showed differences in Tg of B2°C. It is conceivable
that other factors such as the macroscopic integrity
of the sample may have contributed to this effect.
However, the change in dissolution profile is clearly
of potential practical significance. Angell (1995a)
has discussed the concept of ‘polyamorphism’,
whereby materials may exist in distinct disordered
forms, as has been reported for water (Mishima et
al., 1984, 1985, 1991). The generation of such forms
appears to take place under fairly extreme condi-
tions and hence the direct relevance to pharmaceu-
tical materials is far from certain. However, the
suggestion that polyamorphism may exist at all is
of interest.
3.2. The physical stability of amorphous drugs
Given the potential advantages of preparing
drugs in an amorphous form, the question arises as
to why this approach is not used more often. The
single most important reason is undoubtedly the
problems associated with stability, both physical
and chemical. The amorphous state is, by defini-
(Corrigan et al., 1984). In addition, Hill et al.
(1998) have recently studied the glass transitional
behaviour of spray dried lactose using modulated
DSC. Interestingly, Corrigan (1995) has described
how changing the spray drying conditions may
result in the formation of materials with differing
Tg values and physical properties. For example,
Matsuda et al. (1992) prepared amorphous
frusemide using two spray drying protocols and
reported that the resultant materials had differing
Tg values (44.2 and 54.4°C). These changes may be
a result of differences in moisture content but the
study clearly demonstrates the dependence of Tg on
spray drying protocol. Similarly, dichloromethane
solutions of 4%%-O-(4-methoxyphenyl)acetyltylosin
Fig. 11. Concentration-time curves for amorphous MOM in
distilled water at various temperatures [reproduced from Sato
et al. (1981)].
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Fig. 12. Dissolution of crystalline and amorphous indomethacin in water-ethanol (A) and water (B)  glass  crystalline material
[reproduced from Fukuoka et al. (1986)].
tion, metastable with regard to the crystalline
material, hence amorphous drugs will tend to
revert to the crystalline form over a period of
time. Prediction of the timescales involved is
clearly critical and yet may be difficult to achieve.
However, with some knowledge of the fundamen-
tal principles of the crystallisation process and the
physico-chemical properties of the drug in ques-
tion it is possible to make some assessment of the
likelihood of devitrification and to recommend
storage conditions which will minimise the risk of
the process occurring.
Crystallisation from the amorphous state is
governed largely by the same factors that deter-
mine crystallisation from the melt and has been
discussed in more detail by Hancock and Zografi
(1997). In the case of amorphous materials, there
are two conflicting phenomena associated with the
crystallisation process. As the temperature is low-
ered, the rate of nucleation may be expected to
increase. However, the molecular mobility de-
creases as the temperature decreases, particularly
below Tg, thereby slowing the molecular diffusion
and reducing the rate of crystallisation. This is
summarised in Fig. 14 which shows that the max-
imum rate of crystallisation will take place be-
tween Tm and Tg. If a sample is stored below Tg
the risk of devitrification is considerably reduced
due to the molecules having lower mobility with
which to undergo crystal growth; studies on the
crystallisation behaviour of sucrose and lactose
appear to confirm the importance of Tg in this
respect (Makower and Dye, 1956; Saleki-Ger-
hardt and Zografi, 1994). However, it should be
stressed that storage below Tg is far from a guar-
antee of physical stability. Hancock et al. (1995)
have shown that the molecular mobility below Tg
may be sufficient to result in devitrification over
the typical storage periods encountered for phar-
maceutical products. The relationship between Tg
and the stability of glassy pharmaceuticals is
therefore complex; studies comparing the stability
of glassy indomethacin and phenobarbital, both
of which have similar Tg values, showed very
considerable variation in stability profiles even
though both were stored below their Tg values
Fig. 13. Dissolution of felodipine in water-ethanol.  crys-
talline felodipine  glassy felodipine prepared by cooling
under ambient conditions o glassy felodipine prepared by
quenching in liquid nitrogen (Reprinted from Int. J. Pharm.,
68, J. Kerc’ , S. Src’ ic’ , M. Mohar and Smid-Korbar, Some
physiochemical properties of glassy felodipine, pp. 25–33,
Copyright (1991), with permission from Elsevier Science).
D.Q.M. Craig et al. : International Journal of Pharmaceutics 179 (1999) 179–207 195
Fig. 14. Schematic representation of the temperature depen-
dence of the crystallisation process for an amorphous system
[Hancock and Zografi, 1997, after Jolley (1970)].
reasonable guide would be that, if possible, the
sample should be stored at least 50°C below the
Tg value. Clearly, this may not always be practi-
cally possible and, in addition, the stability will
inevitably be system dependent. However, the es-
timate affords the operator some prediction as to
the likelihood of there being a physical stability
problem, which may be of considerable benefit
when at the early stages of planning a formulation
strategy. The authors describe the measurement of
the magnitude of the relaxation endotherm after
storage at different temperatures as a means of
calculating the relaxation time of the sample.
More specifically, the maximum enthalpy recov-
ery (DH) is calculated via:
DH (TgT)·DCp (13)
where Tg and T are the glass and experimental
temperatures and DCp is the change in heat capac-
ity at Tg. The extent of relaxation ft is then
calculated at any time (t) and temperature (T)
conditions via:
ft1 (DHt:DH) (14)
where DHt is the measured enthalpy of recovery
under those conditions. The relaxation time may
then be calculated via the Williams–Watts equa-
tion (Williams and Watts, 1970):
ftexp ( t:t)b (15)
where t is the mean relaxation time constant and
b is an empirical relaxation time distribution
parameter (05b51). By non-linear regression it
is possible to calculate the relaxation times over a
range of conditions, thereby allowing an insight
into the relationship between molecular mobility
and temperature, with clear implications for stor-
age stability. There are a number of difficulties
associated with this approach, including the ne-
cessity to accurately calibrate for DCp and the
difficulty in reliably measuring the magnitude of
the relaxation endotherm; given the associated
shift in baseline, modulated temperature DSC
may in the future prove to be highly useful in
both respects. In addition, it is interesting to note
that in the dielectrics field, from which the
Williams–Watts equation was obtained, there is
growing emphasis on non-empirical analysis of
(Fukuoka et al., 1989). Glassy indomethacin was
reported to be stable over a 2 year period at room
temperature, while phenobarbital devitrified
within 1 week. These differences were ascribed to
variations in steric structure and hydrogen bond-
ing within the two materials. It is also important
to emphasise that even if one is storing the mate-
rial below the Tg of the dry materials, the pres-
ence of trace levels of water may plasticize the
sample sufficiently to bring the Tg value to that of
the storage temperature. Consequently, it is rec-
ommended that if possible the material should be
kept as dry as possible. It has been shown, for
example, that the crystallisation temperature of
salbuterol sulphate may be reduced by the pres-
ence of sorbed water (Ward and Schultz, 1995).
The converse also applies; inclusion of materials
such as PVP, which has a high Tg value (:
180°C), may improve the physical stability of
glassy drugs by raising the Tg value of the binary
system (Fukuoka et al., 1986; Yoshioka et al.,
1995).
Hancock et al. (1995) have argued that the key
issue is that of the temperature in relation to the
Tg at which a glassy drug should be stored in
order to provide a pharmaceutically acceptable
stability profile. From the above discussion it is
clear that storage below Tg is advantageous but is
not a guarantee of stability due to the molecular
mobility which is present below the glass transi-
tion temperature. The authors have argued that a
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non-Debye relaxation behaviour, particularly in
terms of the Dissado–Hill theory (Dissado and
Hill, 1979) which describes the relaxation be-
haviour in terms of many-body interactions rather
than a spread of relaxation times which is in itself
a controversial concept. As yet there has been no
extensive cross-referencing of this theory with re-
gard to glass transition measurements; such an
approach could prove to be highly useful.
The recrystallisation behaviour of the sample
on heating above Tg may also be characterised.
This is commonly seen as an exotherm above the
glass transition, as shown in Fig. 15 for spray
dried lactose. This approach has been studied by
Kerc’ et al. (1991), who describe two main meth-
ods for obtaining kinetic data from the exotherm.
The heat evolution method (Caroll and Manche,
1972; Torfs et al., 1984) involves the measurement
of the rate constant k at any temperature during
the crystallisation process via:
kdH:dt ·[(DHtot(DHrem:DHtot))n]1 (16)
where dH:dt is the heat flow, DHtot is the total
enthalpy, DHrem is the enthalpy corresponding to
the non-crystallised fraction at temperature T and
n is the order of the reaction. An alternative
approach is the variable heating rate method
(Ozawa, 1975) whereby the exothermic peak max-
imum temperature is measured as a function of
heating rate. These approaches are of use in esti-
mating the kinetics of the crystallisation above Tg,
although they are not applicable to the prediction
of the behaviour at temperatures below the glass
transition.
3.3. The chemical stability of amorphous drugs
Numerous reports have shown that rates of
drug degradation may be enhanced in the amor-
phous state compared to the crystalline material.
A series of papers in the 1970s explored the drug
degradation of amorphous and crystalline forms
of drugs. For example, the temperature dependent
degradation of cefoxitin sodium was found to be
markedly enhanced when the drug was prepared
in an amorphous form (Fig. 16, Oberholtzer and
Brenner, 1979), while Pikal et al. (1977) showed
that the degradation rate of a range of b-lactam
Fig. 15. DSC response for spray dried lactose, showing a water loss endotherm (a), a glass transition with accompanying relaxation
endotherm (b), recrystallisation (c) and melting with decomposition (d) (Reprinted from Int. J. Pharm., 161, V.L. Hill, D.Q.M. Craig
and L.C. Feely, Characterisation of spray-dried lactose using modulated differential scanning calorimetry, pp. 95–107, Copyright
(1998), with permission from Elsevier Science).
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Fig. 16. Typical plots of decomposition of (a) crystalline and (b) amorphous cefoxitin sodium at various temperatures  40°C, 
60°C and  80°C [reproduced from Oberholtzer and Brenner (1979)].
antibiotics was enhanced by approximately an
order of magnitude for amorphous as opposed to
crystalline drugs, even when sorbed water levels
were very low. Interestingly, these authors also
reported a discoloration of amorphous
cephalothin sodium prior to the development of a
measurable potency loss.
The mechanism and kinetics of such degrada-
tion reactions have been the subject of some
speculation. As one might expect, the presence of
sorbed water has been reported to increase the
degradation of a range of drugs including insulin
(Strickley and Anderson, 1996) and the aforemen-
tioned b-lactam antibiotics (Pikal et al., 1977). In
the latter study, the authors discussed the kinetics
of the degradation process, finding that in general
the antibiotics showed what appeared to be first
order kinetics as opposed to the sigmoidal curve
expected for solid state reactions (although this
was not the case for all the drugs under study).
However, the authors also reported that the tem-
perature dependence of the decomposition rate
indicated that the activation energy for the pro-
cess was decreasing as the temperature was raised.
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Pikal et al. (1977) suggested that this may be a
function of the rate limiting step of the decom-
position being associated with molecular reorien-
tation processes, whereby certain steric
conditions need to be satisfied in order for the
reaction to occur. In other words, the degrada-
tion may be a function of molecular mobility
and relaxation behaviour. The concept of orien-
tation-specific degradation has been discussed by
several authors. Sukenik et al. (1975, 1977) sug-
gested that the solid state reactivity of aminoben-
zoate derivatives may be associated with their
orientation within the crystal, while Hageman et
al. (1992) have suggested that protein intermolec-
ular reactivity may be higher in the solid state
due to a higher ‘effective concentration’ com-
pared to the solution. Similarly, Strickley and
Anderson (1996) demonstrated that the forma-
tion of the [desamidoA21–GlyA1] dimer was en-
hanced in glassy insulin compared to the
aqueous solution. Pikal et al. (1977) suggested
that as non-Arrhenius behaviour (involving the
activation energy decreasing with temperature) is
characteristic of glassy behaviour in the vicinity
of Tg then the kinetics of degradation may be
associated with relaxation behaviour of the
amorphous solid. This is also consistent with the
observation that the presence of water enhanced
the decomposition rate, as over and above the
presence of a chemical reactant, the water may
be plasticizing the amorphous material and de-
creasing the relaxation time at the temperature of
storage, several other studies have demonstrated
a correlation between the chemical reactivity of
an amorphous material and the glassy behaviour
(Roy et al., 1992; Levine and Slade, 1993).
4. Freeze dried systems
4.1. Introduction
Freeze-drying has been used as a pharmaceuti-
cal unit operation for a number of years for the
low temperature drying of injectable systems.
However, the approach has recently become
more prominent due to the necessity of preparing
novel peptide and proteinaceous drugs in a dry,
stable form which may be easily reconstituted
prior to parenteral administration. The chal-
lenges associated with preparing such formula-
tions have necessitated re-examination of the
physico-chemical principles underlying the freeze
drying process, hence research is ongoing in or-
der to enhance predictability of the chemical and
physical stability of such products. One aspect of
this technology which has been the subject of
considerable study is the glass transitional be-
haviour of both the frozen system prior to dry-
ing and of the finished product. A number of
excellent texts are available on the subject of
freeze drying to which the interested reader is
referred to for more details (Holdsworth, 1987;
Pikal, 1990a,b; Nail and Gatlin, 1993; Pikal,
1993; Franks, 1994). In the interests of brevity,
the description of the freeze drying process given
here is intended as an outline of the amorphous
nature of these systems and is not meant as a
comprehensive discussion of all aspects of the
process.
Freeze drying involves the desiccation of a
substance by crystallisation of ice, followed by
sublimation of water vapour from the solid state
at reduced pressure. Drying at low temperatures
theoretically avoids extensive chemical degrada-
tion and the resulting solid tends to have an
open porous structure that facilitates the rehy-
dration process, this may be essential in life
threatening conditions whereby rapid reconstitu-
tion may be critical. The process has found con-
siderable application in the processing of
pharmaceutical products of biological origin such
as serums, vaccines, peptide drugs and liposomes,
as the stability of freeze-dried solids is usually
much higher than the equivalent aqueous solu-
tion or suspension. In addition, there has also
been considerable interest in the use of freeze
drying as a means of producing rapidly dissolv-
ing oral dosage forms (Corveleyn and Remon,
1997). However, there may be substantial
difficulties associated with both the chemical and
physical stability of freeze dried products, hence
there is considerable interest in establishing the
nature of the interplay between the formulation,
the process used and the stability of freeze dried
systems.
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4.2. The freeze drying process
4.2.1. Initial Freezing
Freezing occurs upon cooling aqueous solutions
to temperatures below 0°C and takes place via ice
nucleation (Ko¨rber, 1988). This process involves
the generation of water aggregates with suffi-
ciently long lifetimes so as to allow interactions
with surrounding water molecules. As the temper-
ature is lowered, molecular mobility decreases and
the lifetimes of the aggregates increase, leading to
nucleation and subsequent crystal growth. It is
important to note that, depending on factors such
as the cooling rate, water may undergo consider-
able supercooling. Ice formation may therefore
take place at temperatures down to 20°C using
rates which are practical in most freeze dryers (for
homogeneous nucleation, undercooling to 40°C
is possible in microlitre volumes, although in
practice heterogeneous nucleation will inevitably
place at higher temperatures during the freeze
drying process). The degree of supercooling in
turn determines the size distribution and mor-
phology of the ice crystals formed, with faster
Fig. 18. Schematic representation of the state diagram of a
glass forming binary system (Reprinted from In: Avis, K.E.,
Lieberman, H.A., Lachman, L. (Eds.), Pharmaceutical Dosage
Forms: Parenteral Medications. Marcel Dekker, New York,
S.L. Nail and L.A. Gatlin, pp. 163–233, Copyright (1993),
with permission from Elsevier Science).
freezing rates giving rise to smaller crystals which
permit more rapid sublimation in the primary
drying step (although secondary drying may be
slower). The resulting product will have a fine
pore structure that facilitates rehydration.
The removal of water to form ice has the effect
of increasing the solute concentration, which
when coupled with cooling causes an increase in
viscosity of the solute phase. This concentration
effect is responsible for many of the deleterious
effects of freeze drying. Nucleation of the solute(s)
may occur leading to crystallisation and the for-
mation of a eutectic system (Fig. 17). For exam-
ple, sodium chloride is expected to form a eutectic
with water at 21°C, although the rate of crystal
growth is slow and complete crystallisation is not
generally observed. If nucleation does not occur
within the timescale of the cooling process then
eventually the remaining ‘solution’ will form a
glass with a viscosity sufficiently high (typically
:1013 Pa.s) to inhibit further ice formation. The
characteristics of this glass may be of considerable
importance in determining the freeze drying pro-
Fig. 17. Schematic representation of the phase diagram of the
NaCl–water eutectic system (Reprinted from In: Avis, K.E.,
Lieberman, H.A., Lachman, L. (Eds.), Pharmaceutical Dosage
Forms: Parenteral Medications. Marcel Dekker, New York,
S.L. Nail and L.A. Gatlin, pp. 163–233, Copyright (1993),
with permission from Elsevier Science).
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tocol and hence will be discussed in more detail
with reference to Fig. 18.
Taking the simplest scenario, the solution is
cooled and ice crystals form, hence the remaining
solution becomes increasingly concentrated until a
saturation value is reached and no further in-
crease in concentration is possible (Cg% ), the sys-
tem is said to be in the maximally freeze
concentrated state (Franks, 1990). The system
undergoes a glass transition and the temperature
at which this occurs is denoted Tg% . However,
rapidly cooled systems containing very low solute
concentrations may exhibit a transition at temper-
atures lower than Tg% because the glass formed will
include more water than the ideal case; this prob-
lem is prevented by the use of lower cooling rates.
It should be noted that Tg% is a very low energy
transition which may be obscured by the ice melt-
ing peak and by the accompanying relaxation
endotherm (if present). Clearly, such a measure-
ment is prone to considerable variation, which is
reflected by the relatively poor consistency of data
for Tg% and Cg% available in the literature, with a
range of values reported for materials such as
sucrose. The corresponding values for this mate-
rial are now generally accepted to be 32°C and
83% sucrose (Slade and Levine, 1988; Franks,
1990).
Identification of Tg% may be further complicated
by the presence of a second transition at slightly
higher temperatures. One system which has been
widely studied in this respect is sucrose, which is
important not only as a pharmaceutical excipient
but in frozen foods. DSC studies of frozen carbo-
hydrate solutions (Ablett et al., 1992; te Booy et
al., 1992) have revealed two transitions below the
onset of melting of ice. DSC studies have shown
that annealing at temperatures immediately below
Tg% yielded a characteristic double transition below
Tm of water, while annealing at the estimated Tg%
gave only one; it was concluded that the two
transitions had coalesced at this temperature
(Ablett et al., 1992). Current thinking is that the
lower transition is the true glass transition while
the second is caused by the irreversible collapse of
the glass and is denoted Ts (softening point, Sha-
laev and Franks, 1995).
4.2.2. Primary drying
During this stage the water separated from the
solute phase in the form of ice during freezing is
removed by sublimation under vacuum. The
product temperature remains relatively constant
and drying follows a pseudo-steady-state rate with
heat removal by sublimation at the same rate as
that of the heat input supplied by the shelves.








where DHs is the heat of sublimation, dm:dt is the
sublimation rate and dQ:dt is the rate of heat








where (PoPc) is the thermodynamic driving-
force for sublimation where P0 is the vapour
pressure of ice in the frozen sample and Pc is the
total pressure in the chamber. (RpRs) is the
total resistance to sublimation, where Rp is the
product resistance and Rs is the resistance of the
stopper in the vial. The rate of heat input can be
expressed as:
dQ:dtAv·Kv (TsTp) (19)
where Av is the cross-sectional area of the vial, Kv
is the vial heat transfer coefficient and (TsTp) is
the heat difference between the shelf and the
product, Ts being the shelf temperature and Tp the
product temperature. P0, the vapour pressure of
the ice in the product, increases exponentially
with temperature, so that an increase in product
temperature will cause a large increase in rate of
sublimation. This also implies that the chamber
pressure should not be set to below that of the
standard vapour pressure of water over ice at the
product temperature since this will decrease the
rate of sublimation. In addition, the dimensions
of the cake influence the effectiveness of drying
since the product resistance will increase as the
thickness of dried cake increases, hindering diffu-
sion of water to the solute:vapour interface. This
has the effect of reducing the rate of sublimation
which will give rise to a temperature gradient in
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the product. At the end of primary drying, sec-
ondary drying will begin spontaneously in some
regions of the product where all the ice has sub-
limed. It is generally assumed that primary dry-
ing has ended when the product temperature is
at the shelf temperature.
Knowledge of the glass transitional behaviour
of the frozen system is extremely useful for
choosing the most appropriate processing
parameters. If during primary drying the product
temperature is raised above Tg% then ice will melt
back into the product, causing softening which
may lead to collapse (discussed below), hence
identification of Tg% and Cg% allows greater pre-
dictability of the effects of drying temperature on
the physical integrity of the sample, allowing
drying to occur at the highest possible tempera-
ture without compromising the physical integrity
of the sample. Given that a temperature increase
of 1°C may lead to a reduction in primary dry-
ing time of 13% (Pikal, 1985), the economic im-
portance of choosing the drying temperature on
a rational basis is clear. Product collapse during
drying has been discussed in detail by Bellows
and King (1972), Pikal and Shah (1990) and
more recently Sun (1997) and is associated with
viscous flow of the amorphous material; this phe-
nomenon leads to an inelegant product but may
also increase reconstitution times and residual
water levels. It is therefore essential to dry the
material below the collapse temperature (Tc)
which, for most practical purposes, is :20°C
above Tg% (Sun, 1997). A range of Tg% and Cg% for
commonly used freeze drying excipients has been
given by Franks (1990).
4.2.3. Secondary drying
This is the term given to the process during
which ‘unfrozen’ water is removed from the
freeze concentrate. Secondary drying is usually
aided by increasing the shelf temperature, usually
to 25–60°C. For this reason it is very important
that all ice has been removed by sublimation
before the temperature is raised in order to pre-
vent melt-back. In the case of amorphous prod-
ucts, the water remaining after primary drying is
trapped in the glassy phase. Initially the rate of
water loss (the first few hours) will be great but a
plateau level is reached beyond which further
water removal (below :2%) is very slow. The
rate of water removal is not proportional to the
concentration of water in the freeze concentrate,
but is controlled by the rate of diffusion to the
solute:vapour interface and the subsequent evap-
oration. As the solid dries, the motion in the
concentrate becomes much slower and conse-
quently diffusion becomes more difficult. Diffu-
sion is a function of the porosity of the
concentrate; small pores caused by extreme su-
percooling before ice formation during the initial
freeze hinder the diffusion of water to the solid:
vapour interface, although chamber pressure (Pc)
and dried cake thickness have little effect on the
rate of secondary drying. The removal of plasti-
cizing water during secondary drying has the ef-
fect of raising the glass transition and hence the
collapse temperature, therefore an ideal sec-
ondary drying protocol would follow the Tg in-
crease of the sample.
4.2.4. Product stability during storage
The glass transition of the freeze dried product
must be well above the subsequent storage tem-
perature in order to prevent collapse, hence de-
termination of Tg for the freeze dried product
has important implications for storage stability
(Nail and Gatlin, 1993). Since collapse occurs
when the sample is unable to hold its own
weight, its apparent value will depend on sample
mass and period of observation (and applied
pressure if mechanical methods of detection are
used).
As yet a limited number of reports have dis-
cussed the significance of product collapse and
implications for stability of pharmaceutical prod-
ucts, although numerous studies may be found
linking the glass transition and stability in the
food science literature, describing phenomena
such as volumetric shrinkage at collapse (Levi
and Karel, 1995), caking and stickiness (Chuy
and Labuza, 1994) and increased rates of nonen-
zymic browning (Buera and Karel, 1995). Early
studies have indicated that modulated DSC may
be particularly useful for measuring transitions
of the dried product in terms of identifying and
quantifying the value of Tg in complex systems
(Kett et al., 1988; Van Winden et al., 1998).
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4.3. Freeze drying of biological products
4.3.1. The effects of water on stability
The principal challenge associated with freeze
drying proteins and other biological products is
loss of activity during freezing, drying or storage;
for example, lactate dehydrogenase may show
complete loss of enzymatic activity after freeze
drying unless protective measures are taken (Pikal,
1993). A number of texts (Franks, 1985; Baffi and
Garnick, 1991; Constantino et al., 1995; Anchor-
doquy and Carpenter, 1996; Chang et al., 1996a,b;
Carpenter et al., 1997; Colaco et al., 1997) are
available which outline the current thinking in this
area.
One highly important issue associated with the
stability of freeze dried proteins is the optimal
residual water of the dried product. Aggregation of
excipient free human growth hormone (hGH) has
been attributed to overdrying (Pikal et al., 1991a),
while excipient free tissue type plasminogen activa-
tor (tPA) was found to aggregate at an enhanced
rate if the residual water level was low (Hsu et al.,
1991a). However, these observations are not the
norm, as in general lower water contents improve
storage stability. For example, the rate of
haemoglobin oxidation at room temperature is
doubled if the residual water content is increased
from 1 to 4% (Pristoupil et al., 1985), while the rate
of degradation of human growth hormone at
elevated temperatures is increased tenfold if the
water content is increased from :1 to 2.5% (Pikal
et al., 1991b). The detrimental effect of water is
usually attributed to the increased mobility and
hence reactivity of solute species. It has been
postulated (Hsu et al., 1991b) that above mono-
layer levels of water the protein has increased
conformational mobility and that additional water
can mobilise reactant species in the amorphous
phase. It should be emphasised that the distribu-
tion of the water throughout the product is also
important. A low overall %w:w water content may
be misleading due to the possibility of localised
regions containing higher water concentrations.
4.3.2. Cryoprotectants
Cryoprotectants are materials which are com-
monly added during the freeze drying process in
order to afford protection of the drug from degra-
dation. The term literally refers to protection dur-
ing freezing or freeze-thawing rather than drying
and hence the term lyoprotectant is preferred if the
additive is capable of preventing degradation dur-
ing the lyophilisation process as a whole. This
distinction may be important as the freeze-drying
process is much harsher than freeze-thawing due to
the additional sublimation stage. For example, the
enzyme L-aspariginase can be freeze-thawed with-
out any loss of activity, but retains only 20%
activity after being exposed to freeze-drying (Hell-
man et al., 1983). Indeed, many cryoprotectants
that are useful additives during freeze-thawing
have little effect during freeze-drying, examples of
such additives being proline and trimethylamine
N-oxide (Carpenter et al., 1991).
The most commonly used cryoprotectants are
sugars, although polymers and amino acids may
also be used. The use of sugars as a means of
protection against freezing or dehydration is well
known in nature. For example, certain organisms
possess the ability to survive complete dehydration
and exist in a state of anhydrobiosis for tens of
decades, without loss of activity upon rehydration.
An example of such an organism is brewers’ yeast,
which is fully active only minutes after rehydration.
This is possible because the organism accumulates
large amounts of saccharides, usually either sucrose
or trehalose (Crowe et al., 1984), and their ability
to survive dehydration can be correlated with the
concentration of sugar present. Both of these
sugars have been investigated as additives to freeze
dried protein formulations (Carpenter and Crowe,
1989; Hall et al., 1995) and liposomes (Van Winden
et al., 1998).
It has been postulated that carbohydrates and
some amino acids stabilise proteins during freezing
by their thermodynamically favourable exclusion
from the protein surface (Arakawa et al., 1991).
This situation arises when it is more favourable for
the stabilizer molecules to interact with each other
than with the protein. In this case the native state
of the protein is favoured because unfolding (or
breaking up of multi-unit proteins to sub-units)
would give greater opportunity for such stabilizer–
protein interactions to occur, and so raise the
Gibbs free energy of unfolding (Arakawa and
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Timasheff, 1982). In contrast, it has been sug-
gested that polymers such as polyvinylpyrrolidone
(PVP) and maltodextrins are believed to exert
their stabilising influence by raising the average
molecular weight, and so increasing the viscosity
of the formulation (Blond, 1994; Anchordoquy
and Carpenter, 1996).
There are two main theories that have been put
forward to account for the stabilising effect of
cryoprotectants during drying and storage,
namely the ‘water substitute’ and the ‘vitrification’
theories. The water substitute theory is thermody-
namically based (Franks et al., 1991; Slade and
Levine, 1991) and assumes that the stabiliser in-
teracts with the protein in the same way as does
water, i.e. that the native state is stabilised be-
cause water lost during the drying process is
replaced by the stabiliser molecules (Prestrelski et
al., 1993a). Studies using FTIR spectroscopy (Pre-
strelski et al., 1993b,c) have indicated that the
conformation of proteins that have bonded sugars
are similar to those in aqueous solution.
The vitrification hypothesis states that the ac-
tivity of the stabilisers stems from their glass-
forming properties. It is assumed that in the
glassy state molecular motion is effectively re-
moved, hence degradation is slowed. Evidence
supporting this theory includes the observation
that mobility and reactivity are both often de-
creased as the product temperature is reduced
below the glass transition temperature region
(Roozen et al., 1991). This hypothesis has also
been used to explain the cryoprotective ability of
high molecular weight polymers in some in-
stances, which are considered to raise the glass
transition temperature of a formulation. How-
ever, a clear link between the Tg of the formula-
tion and the stability of the product has not yet
been established.
5. Conclusions
This discussion has attempted to tie together
some of the concepts and challenges facing the
formulation scientist with respect to the under-
standing and handling of amorphous materials. In
particular, the principles underpinning the glassy
state have been described, along with a consider-
ation of thermal analysis as a means of character-
ising such materials. Two applications have been
discussed, namely the behaviour of amorphous
drugs and freeze dried systems. In all cases, the
need to understand the glass transitional and re-
laxation behaviour of the systems under study has
been stressed.
Amorphous systems are clearly an integral
component of the development of effective dosage
forms and the importance of these materials is
likely to increase both due to the need to develop
oral dosage forms which show favourable
bioavailability profiles and the growing emphasis
on freeze drying for the preparation of proteina-
ceous drugs. By understanding the relationship
between the glassy behaviour and the product
performance characteristics of these materials it is
therefore possible to approach formulation strate-
gies on a more rational basis.
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